Safety and Efficacy of Senolytic UBX1325 in Diabetic Macular Edema

/in , /by

https://evidence.nejm.org/doi/full/10.1056/EVIDoa2400009

You might also like
Pathological angiogenesis in retinopathy engages cellular senescence and is amenable to therapeutic elimination via BCL-xL inhibition
UBX1325, a small molecule inhibitor of Bcl-xL, attenuates vascular dysfunction in two animal models of retinopathy
Neutrophil extracellular traps target senescent vasculature for tissue remodeling in retinopathy
Therapeutic targeting of cellular senescence in diabetic macular edema: preclinical and phase 1 trial results
Cellular Senescence Is Associated With Human Retinal Microaneurysm Formation During Aging
Senescence-associated secretory phenotype contributes to pathological angiogenesis in retinopathy
Cellular Senescence Is Associated With Human Retinal Microaneurysm Formation During Aging

©2025 Unity Biotechnology. All Rights Reserved. Terms & Conditions | Privacy Policy

Therapeutic targeting of cellular senescence in diabetic macular edema: preclinical...